Loading people...
Ferran Marti is an Associate at Nina Capital, a specialized venture capital firm based in Barcelona, Spain. He holds a joint degree in biomedical engineering from the Universitat de Barcelona and the Universitat Politècnica de Catalunya, providing a technical foundation for evaluating innovative healthcare startups. Marti initially joined the European micro-VC firm as an Investment Analyst in 2021 before being promoted to his current position. In this capacity, he is responsible for sourcing, conducting comprehensive due diligence, and supporting pre-seed and seed-stage companies operating across the United States and Europe. He is actively involved in deploying capital from the firm's specialized health tech funds as of 2024, leveraging his academic background to assess complex medical technologies. His current focus centers on identifying early-stage investment opportunities within the digital health, medical device, and broader health technology sectors.
Ferran Marti is a key Associate at Nina Capital, a prominent venture capital firm renowned for its strategic investments in the burgeoning healthcare technology sector. In his capacity, Ferran plays a crucial role in the firm's investment process, from initial deal sourcing and due diligence to portfolio management support. His work is instrumental in identifying the next generation of innovative companies poised to revolutionize healthcare delivery and patient outcomes.
Nina Capital's investment thesis centers on early-stage companies that leverage technology to address critical challenges within healthcare. Ferran's focus areas align closely with this mission, encompassing a broad spectrum of digital health innovations. This includes, but is not limited to, artificial intelligence and machine learning applications in diagnostics and treatment, remote patient monitoring platforms, telehealth solutions, health data analytics, and software that enhances operational efficiency for healthcare providers. He is particularly interested in startups that demonstrate strong potential for scalability, a clear value proposition, and a passionate founding team.
Ferran's career background provides a solid foundation for his contributions to Nina Capital. While specific details of his prior roles are not publicly detailed, professionals in his position typically bring a blend of experience from finance, consulting, or directly from the health technology industry. This diverse background equips him with the analytical rigor to assess complex business models and the industry insight to understand market trends and technological advancements. His expertise helps Nina Capital make informed decisions that drive significant impact in the healthcare landscape.
As an Associate, Ferran is deeply involved in supporting Nina Capital's portfolio companies, helping them navigate growth challenges and achieve their strategic milestones. While individual notable investments are typically attributed to the firm as a whole, Ferran's analytical contributions and strategic insights are vital to the success of the companies Nina Capital backs. He works closely with founders, offering guidance and connecting them with resources to accelerate their development and market penetration. His dedication to fostering innovation and supporting entrepreneurial talent underscores his commitment to advancing healthcare through technology. Ferran Marti is an integral part of Nina Capital's mission to shape the future of healthcare.
Ferran Marti is an Associate at Nina Capital, a venture capital firm specializing in healthcare technology investments. He is involved in identifying, evaluating, and supporting early-stage digital health startups.
Ferran Marti, through Nina Capital, invests in early-stage healthcare technology companies. His focus areas include digital health, AI and machine learning in healthcare, remote patient monitoring, telehealth, health data analytics, and software solutions for healthcare providers.
Ferran Marti works as an Associate at Nina Capital, a venture capital firm dedicated to investing in innovative healthcare technology companies.